LTFS
VRTX icon

Ladenburg Thalmann Financial Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$2.15M Buy
10,283
+1,513
+17% +$306K 0.01% 836
2019
Q3 		$1.48M Buy
8,770
+3,683
+72% +$652K 0.01% 979
2019
Q2 		$932K Sell
5,087
-1,081
-18% -$189K 0.01% 1278
2019
Q1 		$1.14M Sell
6,168
-2,626
-30% -$485K 0.01% 1099
2018
Q4 		$1.47M Buy
8,794
+3,553
+68% +$616K 0.01% 821
2018
Q3 		$1.01M Buy
5,241
+516
+11% +$91.9K 0.01% 1113
2018
Q2 		$771K Hold
4,725
– – 0.01% 1227
2018
Q1 		$771K Buy
4,725
+247
+6% +$40.3K 0.01% 1227
2017
Q4 		$671K Sell
4,478
-1,977
-31% -$293K 0.01% 1326
2017
Q3 		$983K Buy
6,455
+1,876
+41% +$282K 0.01% 1007
2017
Q2 		$590K Buy
4,579
+1,716
+60% +$207K 0.01% 1279
2017
Q1 		$312K Buy
2,863
+405
+16% +$35.7K ﹤0.01% 1615
2016
Q4 		$184K Sell
2,458
-89
-3% -$7.24K ﹤0.01% 1877
2016
Q3 		$222K Sell
2,547
-35
-1% -$3.31K ﹤0.01% 1691
2016
Q2 		$221K Sell
2,582
-18
-0.7% -$1.55K ﹤0.01% 1619
2016
Q1 		$206K Sell
2,600
-1,684
-39% -$152K ﹤0.01% 1589
2015
Q4 		$538K Buy
4,284
+1,527
+55% +$184K 0.01% 985
2015
Q3 		$289K Buy
2,757
+694
+34% +$89.2K 0.01% 1241
2015
Q2 		$257K Buy
2,063
+415
+25% +$52.3K ﹤0.01% 1427
2015
Q1 		$195K Sell
1,648
-34
-2% -$4.07K ﹤0.01% 1593
2014
Q4 		$196K Buy
1,682
+100
+6% +$11.3K ﹤0.01% 1437
2014
Q3 		$173K Buy
1,582
+51
+3% +$4.86K ﹤0.01% 1290
2014
Q2 		$140K Sell
1,531
-514
-25% -$36K ﹤0.01% 1400
2014
Q1 		$147K Buy
2,045
+170
+9% +$13.5K ﹤0.01% 1296
2013
Q4 		$140K Sell
1,875
-352
-16% -$24.5K ﹤0.01% 1261
2013
Q3 		$163K Buy
2,227
+50
+2% +$3.98K 0.01% 1104
2013
Q2 		$177K Buy
+2,177
New +$160K 0.01% 1035

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Ladenburg Thalmann Financial Services's VRTX Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its Vertex Pharmaceuticals (VRTX) stake by 17% in Q4 2019, buying an estimated $306K and bringing the position to 10,283 shares worth $2.15M. The position accounts for 0.01% of the portfolio, ranked #836.

Ladenburg Thalmann Financial Services first reported a position in VRTX in Q2 2013 and has held it in 27 quarters since. 814 funds tracked by Wall St. Rank hold VRTX as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 10,283 shares of Vertex Pharmaceuticals worth $2.15M as of Q4 2019.
  • Ladenburg Thalmann Financial Services bought 1,513 Vertex Pharmaceuticals shares in Q4 2019, an estimated $306K.
  • Vertex Pharmaceuticals made up 0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #836 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 27 quarters since.
  • 814 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.